HDAC-IN-89
HDAC-IN-89 is an inhibitor of HDAC1 (IC50: 0.95 nM), HDAC2 (IC50: 0.86 nM), HDAC3 (IC50: 1.06 nM) and HDAC8 (IC50: 4.24 nM). HDAC-IN-89 blocks the cell cycle and induces apoptosis. HDAC-IN-89 has anti-tumor activity.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- 화학식: C24H35F2N5O5S2
- 분자량:575.69
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
IC50 & Target
[1]|
HDAC1 0.95 nM (IC50) |
HDAC2 0.86 nM (IC50) |
HDAC3 1.06 nM (IC50) |
HDAC8 4.24 nM (IC50) |
HDAC6 >1000 nM (IC50) |
In Vitro
HDAC-IN-89 (Compound 12) (0-10000 nM, 72 h) shows cytotoxicity against both NCI-H1975 (IC50: 0.57 μM) and HT-29 (IC50: 0.17 μM) cancer cells, but shows significantly reduced cytotoxicity against both WRL-68 (IC50: 2.6 μM) and HEK293 (IC50: 1.0 μM) normal cells[1].
HDAC-IN-89 (250 nM-1 μM, 48 h) induces cell cycle arrest in the G0/G1 phase of HT-29 cells and significantly promotes apoptosis of early and late cells at the corresponding concentrations[1].
HDAC-IN-89 (0-40 μM) has a small inhibitory effect on the hERG potassium channel (21%), indicating a low risk of cardiotoxicity[1].
HDAC-IN-89 (0.1 μM, 7-60 min) shows moderate metabolic stability (MF%: 30%-70%) and rapid clearance (Clint: 21.7-43.7 mL/min/g) in mouse, rat and human liver microsomes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Tumor cells (NCI-H1975 cells, HT-29 cells) and normal cells (WRL-68 cells, HEK293 cells)
-
Concentration:0-10000 nM
-
Incubation Time:72 h
-
Result:Inhibited the activity of two cancer cells, NCI-H1975 (IC50: 0.57 μM) and HT-29 (IC50: 0.17 μM).
Reduced the toxicity to two normal cells, WRL-68 (IC50: 2.6 μM) and HEK293 (IC50: 1.0 μM).
-
Cell Line:HT-29 cells
-
Concentration:250 nM, 500 nM and 1μM
-
Incubation Time:48 h
-
Result:Induced cell cycle arrest in HT-29 cells at the G0/G1 phase (%G0/G1: 55.0%/57.2%/74.0%).
-
Cell Line:HT-29 cells
-
Concentration:250 nM and 500 nM
-
Incubation Time:48 h
-
Result:Promoted apoptosis of early cells (14.3%/19.7%) and late cells (7.57%/11.1%) at the corresponding concentrations (250 nM/500 nM).
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NCI-H1975 xenograft model[1]
-
Dosage:2.2 mg/kg and 11 mg/kg
-
Administration:Intraperitoneal injection (i.p.), once every 3 days for 21 days
-
Result:Inhibited tumor growth (63.5% and 87.9%).
Had no significant changes in body weight compared to the same dose of Romidepsin (2.2 mg/kg).
Chemical Information
-
분자량 575.69
-
화학식 C24H35F2N5O5S2
-
SMILES
CC(C)[C@@H](C(N[C@H](/C=C/CCSSC[C@@H](C1=O)NC2=O)C(F)(F)C(N[C@@H]2C(C)C)=O)=O)NC(/C(N1)=C/C)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)